Pfizer Unveils Promising Early Data On COVID-19, Sends Moderna Shares Down

Preliminary Results From 45 Subjects

Pfizer and BioNTech appear to have the upper hand on mRNA rivals Moderna, but Phase III results will be the real test.

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.

More from COVID-19

More from Scrip